SCIENTIFIC STUDY: PRO-LONGEVITY
ANTI-AGING STRATEGY TO MAINTAIN THE LIFE =
ANTI-INFLAMMATORY + ANTIOXIDANTS
Paladin Pharma has been assigned to AMIA, the Italian Association of Anti-Aging Physicians, the construction of the first of a series, scientific study of highly qualifying, double-blind study with a significant number of subjects, in order to investigate the characteristics of an innovative formulation nutraceutical, able to confer a cellular protection active against a premature aging induced by oxidative stress and by the processes attributable to chronic inflammation. The study, in progress, is followed directly by the Department of Immunopathology, University of Palermo, under the direction of prof. Calogero Caruso, also Chairman of our Scientific Committee and with the collaboration of Prof. Sonya Vasto.
AGING CELL
65% of cellular aging is caused by our lifestyle and is then modified according tospecific strategies based on the integration of antioxidants and anti-inflammatory. The theoryunified dell'aging is a clear example: The new nutraceutical election Pro-Longevity is born with the aim to combat premature aging and slow down the phone and comes with two innovative formulations, can also adapt to the different process that endocrinosenescenza is to characterize the sexes. The two distinct formulations of the Pro-Longevity, here are then to be the only solution, short-present in the context of the Italian market of nutraceuticals and medical devices, which takes into account the different hormonal decline in men and women and in this sense contrasts respectively cellular aging-induced decline in androgen and estrogen decline.
Pro-longevity contains the exclusive AgeProtectiono510 patented and tested both in vitro and in vivo.The in vitro tests, already effected, demonstrates the efficacy of the formulation in reducing the inflammatory processesinduced in cell cultures of fibroblasts and the ability to increase the cellular defense systems (SOD,Glutathione peroxidase, catalase).
The in vivo study performed double-blind randomized placebo in 100 subjects is on-going.The experimental protocol EFSA considers the following parameters:- Modified Comet assay to monitor the protection conferred by prepared at the DNA level- Determination of F2-isoprostanes in urine by gas-chromatography to evaluate the protectionof the preparation at the level of cellular lipids, such as cell membranes- Determination of oxidized LDL-always for the evaluation of the protective effect of the preparation incomparisons of cellular lipids- Advanced Glycation Endpoints: assessment of glycation end products- Evaluation of carotenoids in the skin.Purpose is also given secondary objective is not to achieve a synergistic able to activate thesystem of sirtuins or "longevity genes."
Pro-longevity Men and Women